Home News

DORIA® presentation

The fast onset of action long-acting injectable of risperidone. Based on our ISM® patented technology.

Wed, 25/10/2017 - 13:50 0 min
Download related document
No votes yet
 
Related
ROVI informs on the evaluation process to obtain marketing authorisation for...
Laboratorios Farmacéuticos ROVI, S.A. (ROVI) informs on the evaluation process to obtain marketing authorisation for Risvan® (Risperidone...
2 min
16/02/2023
ROVI’s Alcalá de Henares plant receives the visit of the Romanian Health...
Madrid, 6th February, 2023 This Monday, the Romanian Minister of Health, Alexandru Rafila, visited the ROVI plant in Alcalá de Henares....
2 min
06/02/2023
ROVI leads the BioElast Consortium approved in the 2021 Call for Projects in...
Madrid: 28 of December 2022 The project entitled “Bioreactors and Biostains with Heparin for the Regeneration of Elastic Tissues (...
1 min
28/12/2022